7:53 AM
 | 
Nov 16, 2018
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Seal Rock's ASK1 inhibitor improves NASH symptoms in mice

Seal Rock Therapeutics Inc. (Seattle, Wash.) said lead candidate SRT-015 significantly improved metabolic parameters and liver-specific pathology in a mouse model of non-alcoholic steatohepatitis (NASH). The liver-selective apoptosis signal-regulating kinase 1 (ASK1;...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >